Melanoma cell migration on vitronectin: Regulation by components of the plasminogen activation system

International Journal of Cancer

Volumn 71, Issue 1, 1997, Pages 116-122

  Stahl, Andreas ^a   Mueller, Barbara M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; VITRONECTIN;

ARTICLE; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MELANOMA CELL; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL;

CELL MOVEMENT; CHEMOTAXIS; HUMANS; MELANOMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, CELL SURFACE; RECEPTORS, VITRONECTIN; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR; VITRONECTIN;

EID: 0030935818     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970328)71:1<116::AID-IJC19>3.0.CO;2-G     Document Type: Article

References (54)

1. AKIYAMA, S.K. and YAMADA, K.M., Synthetic peptides competitively inhibit both direct binding to fibroblasts and functional biological assays for the purified cell-binding domain of fibronectin. J. biol. Chem., 260, 10402-10405 (1985).
2. 3 subunit with tumor progression. Cancer Res., 50, 6757-6764 (1990).
3. ASHKENAS, J., DAMSKY, C.H., BISSELL, M.J. and WERB, Z., Integrins, signaling and the remodeling of the extracellular matrix. In: D.A. Cheresh and R.P. Mecham (eds.), Integrins: molecular responses to the extracellular matrix, pp. 79-109, Academic Press, New York (1994).
4. BEHRENDT, N., RØNNE, E. and DANØ, K., The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol. Chem. Hoppe-Seyler, 376, 269-279 (1995).
5. BIANCHI, E., COHEN, R.L., DAI, A., THOR, A.T., SHLIMAN, M.A. and SMITH, H.S., Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int. J. Cancer, 60, 597-603 (1995).
6. BIANCHI, E., COHEN, R.L., THOR, A.T., TODD, R.F. III, MIZUKAMI, I.F., LAWRENCE, D.A., LJUNG, B.M., SHUMAN, M.A. and SMITH, H.S., The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res., 54, 861-866 (1994).
7. Busso, N., MASUR, S.K., LAZEGA, D., WAXMAN, S. and OSSOWSKI, L., Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J. Cell Biol., 126, 259-270 (1994).
8. CARRIERO, M.V., FRANCO, P., DEL VECCHIO, S., MASSA, O., BOTTI, G., D'AIUTO, G., STOPPELLI, M.P. and SALVATORE, M., Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res., 54, 5445-5454 (1994).
9. CIAMBRONE, G.J. and MCKEOWN-LONGO, P.J., Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 Cells. J. biol. Chem., 267, 13617-13622 (1992).
10. CONESE, M. and BLASI, F., Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation. Biol. Chem. Hoppe-Seyler, 376, 143-155 (1995).
11. CROWLEY, C.W., COHEN, R.L., LUCAS, B.K., LIU, G., SHUMAN, M.A. and LEVINSON, A.D., Prevention of metastasis by inhibition of the urokinase receptor. Proc. nat. Acad. Sci. (Wash.), 90, 5021-5025 (1993).
12. DANø, K., ANDREASEN, P.A., GRONDAHL-HANSEN, J., KRISTENSEN, P., NIELSEN, L.S. and SKRIVER, L., Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res., 44, 139-266 (1985).
13. DECLERCK, P.J., DEMOL, M., ALESSI, M.C., BAUDNER, S., PAQUES, E.P., PREISSNER, K.T., MULLER-BERGHAUS, G. and COLLEN, D., Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a mullimeric form of S protein (vitronectin). J. biol. Chem., 263, 15454-15461 (1988).
14. DENG, G., CURRJDEN, S.A., WANG, S., ROSENBERG, S. and LOSKUTOFF, D.J., Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol., 134, 1563-1571 (1996).
15. DEVRIES, T., QUAX, P.H., DENUN, M., VERRIJP, K.N., VERHEIJEN, J.H., VERSPAGET, H.W., WEIDLE, U.H., RUITER, D.J. and VAN MUIJEN, G., Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Amer. J. Pathol., 144, 70-81 (1994).
16. DIMILLA, P.A., BARBEE, K. and LAUFFENBURGER, D.A., Mathematical model tor the effects of adhesion and mechanics on cell migration speed. Biophys. J., 60, 15-37 (1991).
17. DIMILLA, P.A., STONE, J.A., QUINN, J.A., ALBELDA, S.M. and LAUFFENBURGER, D.A., Maximal migration of human smooth muscle cells on fibronectin and type IV collagen occurs at an intermediate attachment strength. J. Cell Biol., 122, 729-737 (1993).
18. DUFFY, M.J., Proteases as prognostic markers in cancer. Clin. Cancer Res., 2, 613-618 (1996).
19. GLADSON, C.L. and CHERESH, D.A., Glioblastoma expression of vitronectin and the αVβ3 integrin. Adhesion mechanism for transformed gliai cells. J. clin. Invest., 88, 1924-1932 (1991).
20. GLADSON, C.L. and CHERESH, D.A., The αV integrins. In: Y. Takada (ed.), Integrins: the biological problem, pp. 83-99. CRC Press. Boca Raton (1994).
21. GYETKO, M.R., TODD, R. III, WILKINSON, C.C. and SITRIN, R.G., The urokinase receptor is required for human monocyte chemotaxis in vitro. J. clin. Invest., 93, 1380-1387 (1994).
22. HEARING, V.J., LAW, L.W., CORTI, A., APPELLA, E. and BLASI, F., Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res., 48, 1270-1278 (1988).
23. 5. J. biol. Chem., 270, 26232-26238 (1995).
24. JAENICKE, F., PACHE, L., SCHMITT, M., ULM, K., THOMSSEN, C., PRECHTL. A. and GRAEFF, H., Both the cytosols and detergent extracts in breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator type I. Cancer Res., 54, 2527-2530 (1994).
25. KOOK, Y.H., ADAMSKI, J., ZELENT, A. and OSSOWSKI, L., The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J., 13, 3983-3991 (1994).
26. KUO, S.C. and LAUFFENBURGER, D.A., Relationship between receptor/ligand binding affinity and adhesion strength. Biophys. J., 65, 2191-2200 (1993).
27. LOFTUS, J.C., SMITH, J.W. and GINSBERG, M.H., Integrin-mediated cell adhesion: the extracellular face. J. biol. Chem., 269, 25235-25238 (1994).
28. MIGNATTI, P. and RIFKIN, D.B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev., 73, 161-195 (1993).
29. MIMURO, J. and LOSKUTOFF, D.J., Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. J. biol. Chem., 264, 5058-5063 (1989).
30. MIN, H.Y., DOYLE, L.V., VITT, C.R., ZANDONELLA, C.L., STRATTONTHOMAS, J., SHUHMAN, M.A. and ROSENBERG, S., Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res., 56, 2428-2433 (1996).
31. MOSER, T.L., ENGHILD, J.J., PIZZO, S.V. and STACK, M.S., Specific binding of urinary-type plasminogen activator (U-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells. Biochem. J., 307, 867-873 (1995).
32. MUELLER, B.M., YU, Y.B. and LAUG, W.E., Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc. nat. Acad. Sci. (Wash.), 92, 205-209 (1995).
33. NIP, J., RABBANI, S.A., SHIBATA, H.R. and BRODT, P., Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. J. clin. Invest., 95, 2096-2103 (1995).
34. ODEKON, L.E., SATO, Y. and RIFKIN, D.B., Urokinase-type plasminogen activator mediates basic ribroblast growth factor-induced bovine endothelial cell migration independent of its proteolvtic activity. J. cell. Physiol., 150, 258-263 (1992).
35. OKADA, S.S., TOMASZEWSKI, J.E. and BARNATHAN, E.S., Migrating vascular smooth muscle cells polarize cell surface urokinase receptors after injury in vitro. Exp. Cell Res., 217, 180-187 (1995).
36. OSSOWSKI, L. and REICH, E., Antibodies to plasminogen activator inhibit human tumor metastasis. Cell. 35, 611-619 (1983).
37. PAPPOT, H., GARDSVOLL, H., ROMER, J., PEDERSEN, A.N., GRONDAHLHANSEN, J., PYKE, C. and BRUNNER, N., Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. Biol. Chem. Hoppe-Seyler. 376, 259-267 (1995).
38. PEPPER, M.S., VASSALLI, J.D., MONTESANTO, R. and ORCI, L., Urokinasetype plasminogen activator is induced in migrating capillary endothelial cells. J. Cell Biol., 105, 2535-2541 (1987).
39. POLLANEN, J., HEDMAN, K., NIELSEN, L.S., DANØ, K. and VAHERI, A., Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J. Cell Biol., 106, 87-95 (1988).
40. PREISSNER, K.T., Structure and biological role of vitronectin. Ann. Rev. Cell Biol., 7, 275-310 (1991).
41. 5-mediated adhesion of a human keratinocyte cell line (HaCaT) to vitronectin. Exp. Cell Res., 220, 274-282 (1995).
42. RUOSLAHTI, E., Control of cell motility and tumor invasion by extracellular matrix interactions. Brit. J. Cancer, 66, 239-242 (1992).
43. SCHWARTZ, M.A., SCHALLER, M.D. and GINSBERG, M.H., Integrins: emerging paradigms of signal transduction. Ann. Rev. Cell Dev. Biol., 11, 549-599 (1995).
44. SEIFFERT, D., CIAMBRONE, G., WAGNER, N.V., BINDER, B.R. and LOSKUTOFF, D.J., The somatomedin B domain of vitronectin. Structural requirements for the bindins and stabilization of active type 1 plasminoeen activator inhibitor. J. biol. Chem., 269, 2659-2666 (1994).
45. SITRTN, R.G., TODD, R.F. III, PETTY, H.R., BROCK, T.G., SHOLLENBERGER, S.B., ALBRECHT, E. and GYETKO, M.R., The urokinase receptor (CD87) facilitates CD1 lb/CD18-mediated adhesion of human monocytes. J. clin. Invest., 97, 1942-1951 (1996).
46. SOFF, G.A., SANDEROWITZ, J., GATELY, S., VERRUSIO, E., WEISS, I., BREM, S. and KWAAN, H.C., Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor- associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J. clin. Invest., 96, 2593-2600 (1995).
47. STAHL, A. and MUELLER, B.M., Binding of urokinase to its receptor promotes misration and invasion of human melanoma cells in vitro. Cancer Res., 54, 3066-3071 (1994).
48. VASSALLI, J.D., SAPPINO, A.P. and BELIN, D., The plasminogen activator/ plasmin system. J. clin. Invest., 88, 1067-1072 (1991).
49. WALTZ, D.A. and CHAPMAN, H.A., Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J. biol. Chem., 269, 14746-14750 (1994).
50. WALTZ, D.A., SAILOR, L.Z. and CHAPMAN, H.A., Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors. J. clin. Invest., 91, 1541-1552 (1993).
51. WEI, Y., LUKASHEV, M., SIMON, D.I., BODARY, S.C., ROSENBERG, S., DOYLE, M.V. and CHAPMAN, H.A., Regulation of intesrin function by the urokinase receptor. Science, 273, 1551-1555 (1996).
52. WEI, Y., WALTZ, D.A., RAO, N., DRUMMOND, R.J., ROSENBERG, S. and CHAPMAN, H.A., Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. biol. Chem., 269, 32380-32388 (1994).
53. YATAHOGO, T., IZUMI, M., KASHIWAGI, H. and HAYASHI, M., Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell. Struct. Funct., 13, 281-292 (1988).
54. 5-directed cell migration. J. biol. Chem., 271, 29393-29399 (1996).